Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience

Javier Checa, Óscar Javier Blanco Núñez, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Daniel Rivera, MD, Alejandro Avendaño Pita, MD, Antonio velasco Guardado, PhD, Miguel Alcoceba, PhD, Luis Miguel Chinchilla Tábora, MD, Dolores Caballero, MD, Lucia Lopez Corral, PhD MD

Blood (2018) 132 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2018-99-114587

Published: 2018

Journal Articles

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Alvaro Veiga, MD, Alba Redondo, MD, Miriam López-Parra, MD, Olga López-Villar, MD, Eva Villarón, Maria Díez-Campelo, MD PhD, Daniel Rivera, MD, Natalia Espinosa, MD, Nerea Arratibel, MD, Mónica Baile, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Lourdes Vázquez, MD, Lucía López Corral, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Fermin Sanchez-Guijo, MD PhD

Blood (2017) 130 (Supplement 1): 1981.

https://doi.org/10.1182/blood.V130.Suppl_1.1981.1981

Published: 2017

Journal Articles

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Blood (2017) 130 (Supplement 1): 3208.

https://doi.org/10.1182/blood.V130.Suppl_1.3208.3208

Published: 2017

Journal Articles

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Daniel Rivera, MD, Jose Maria Bastida, MDPhD, Lucia Lopez Corral, PhD MD, Fermin Sanchez-Guijo, MD PhD, Lourdes Vázquez, MD, Monica Cabrero, MD, Estefania Pérez-López, MD, Miriam López-Parra, MD, Ana A. Martín, MD, Javier Carrillo, MD, Alejandro Avendaño, MD, Alvaro Veiga, MD, Monica Baile, MD, Nerea Arratibel, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Jose Ramon González-Porras, MDPhD

Blood (2017) 130 (Supplement 1): 3222.

https://doi.org/10.1182/blood.V130.Suppl_1.3222.3222

Published: 2017

Journal Articles

The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

Natasha Kekre, MD FRCPC, Francisco J Marquez-Malaver, RN, Dolores Caballero, MD, Jl Piñana, MD, Albert Esquirol, MD, Robert J. Soiffer, MD, Monica Cabrero, MD, MJ Terol, Rodrigo Martino, MD PhD, Joseph H. Antin, MD, L Lopez Corral, Carlos Solano, Philippe Armand, MD PhD, Jose A. Perez-Simon, MD, PhD

Blood (2015) 126 (23): 2007.

https://doi.org/10.1182/blood.V126.23.2007.2007

Published: 2015

Journal Articles

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

Ali N. Chamseddine, MD, Yue Wei, PhD, Monica Cabrero, MD, Irene Ganan-Gomez, PhD MSc, Simona Colla, PhD, Koichi Takahashi, MD, Hui Yang, MD PhD, Marcos R Estecio, PhD, Zachary S. Bohannan, MA, Sherry Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD, Hagop M Kantarjian, MD, Elias Jabbour, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5227.

https://doi.org/10.1182/blood.V126.23.5227.5227

Published: 2015

Journal Articles

Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents

Binsah George, MD, Elias Jabbour, MD, Monica Cabrero, MD, Nitin Jain, MD, Naval Daver, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Zach Bohannan, Jorge E. Cortes, MD, Michael J Keating, MBBS, Susan O'Brien, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 2278.

https://doi.org/10.1182/blood.V124.21.2278.2278

Published: 2014

Journal Articles

Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience

Adolfo Diaz Duque, MD, Monica Cabrero, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Elias Jabbour, MD, Guillermo Garcia Manero, MD, Koji Sasaki

Blood (2014) 124 (21): 1924.

https://doi.org/10.1182/blood.V124.21.1924.1924

Published: 2014

Journal Articles

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

Blood (2014) 124 (21): 3277.

https://doi.org/10.1182/blood.V124.21.3277.3277

Published: 2014

Journal Articles

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Yue Wei, Monica Cabrero, MD, Yu Jia, Hong Zheng, Hui Yang, MD, PhD, Zhihong Fang, Zach Bohannan, Rui Chen, PhD, Hui Wang, PhD, Simona Colla, Xia Wang, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 3241.

https://doi.org/10.1182/blood.V124.21.3241.3241

Published: 2014

Journal Articles

Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes

Yue Wei, Amit Verma, MD, Monica Cabrero, MD, Yu Jia, Hong Zheng, Zhihong Fang, Yiting Yu, PhD, Simona Colla, Zach Bohannan, Teresa V. Bowman, PhD, Jacqueline Boultwood, PhD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4663.

https://doi.org/10.1182/blood.V124.21.4663.4663

Published: 2014

Journal Articles

Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up

Monica Cabrero, MD, Elias Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge E. Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan Kadia, MD, Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4664.

https://doi.org/10.1182/blood.V124.21.4664.4664

Published: 2014

Journal Articles

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Monica Cabrero, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge E. Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Betul Oran, MD, Richard E. Champlin, Hagop Kantarjian, MD, Elias Jabbour, MD

Blood (2014) 124 (21): 4666.

https://doi.org/10.1182/blood.V124.21.4666.4666

Published: 2014

NARROW

Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents

Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes

Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only